Novavax, Inc. (NVAX)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$9.70-2.90%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Novavax, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
FY 2026 · Q4
Revenue	—	105.59M
EPS	—	-0.049
FY 2026 · Annual
Revenue	$235M–$275Mnon-GAAP	383.71M
Supply revenue	$40M–$50Mnon-GAAP	—
EPS	—	-0.595
FY 2027 · Annual
Revenue	—	311.63M
EPS	—	0.026

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Target 2026 R&D and SG&A expenses of $325M	A supporting condition in Novavax, Inc.'s published investment case. The stated target is <= $325M combined R&D and SG&A expenses.	Intact	Combined R&D and SG&A expenses exceed $325M in FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. Management maintained Non-GAAP combined R&D and SG&A expense guidance at $310-$340 million for 2026, improving GAAP guidance slightly in 2026-Q2. Actual R&D expenses decreased from $95 million in 2026-Q1 to $71 million in 2026-Q2, and SG&A expenses decreased slightly from $29 million to $27 million. The trajectory shows management delivering cost discipline consistent with their guidance. Delivery assessment Oct 24, 2026
License agreement with Pfizer for Matrix-M	The company secured a licensing deal with Pfizer for Matrix-M, supporting future revenue.	Intact	Loss or termination of Matrix-M licensing agreement with Pfizer	License active (Jan 2026) Jan 2026 Pfizer license active; Aug-Sep 2026 news highlights Matrix-M momentum and partnership expansion. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Achieve 2026 revenue of $230M-$270M	A primary condition in Novavax, Inc.'s published investment case. The stated target is >= $230M revenue.	Intact	Revenue falls below $230M in FY26	Revenue: $56.698M FY2026-Q2; GAAP. Published target: >= $230M revenue. Target period is not explicitly aligned with this observation. Source published Aug 6, 202656,698,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: feacd4ee-ef0e-4400-9250-856ddd8e34f0. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$0.03

$-0.27 → $0.03 · observed estimates

FY2027 revenue$0.31B

$0.26B → $0.31B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-0.27	$257,226,069	7 / 7
2026-07-25	$-0.25	$258,467,510	9 / 9
2026-07-26	$-0.25	$258,467,510	9 / 9
2026-07-27	$-0.27	$257,226,069	7 / 7
2026-07-28	$-0.25	$258,467,510	9 / 9
2026-07-29	$-0.25	$258,467,510	9 / 9
2026-07-30	$-0.25	$258,467,510	9 / 9
2026-07-31	$-0.25	$258,467,510	9 / 9
2026-08-01	$-0.27	$257,226,069	7 / 7
2026-08-02	$-0.25	$258,467,510	9 / 9
2026-08-03	$-0.25	$258,467,510	9 / 9
2026-08-04	$-0.25	$258,467,510	9 / 9
2026-08-05	$-0.18	$258,467,510	9 / 9
2026-08-06	$-0.18	$258,467,510	9 / 9
2026-08-07	$-0.18	$272,226,069	7 / 7
2026-08-08	$-0.11	$269,834,170	8 / 9
2026-08-09	$-0.11	$269,834,170	8 / 9
2026-08-10	$-0.11	$269,834,170	8 / 9
2026-08-12	$-0.16	$266,174,810	8 / 9
2026-08-13	$-0.18	$272,226,069	7 / 7
2026-08-14	$-0.18	$272,226,069	7 / 7
2026-08-15	$-0.18	$272,226,069	7 / 7
2026-08-16	$-0.18	$272,226,069	7 / 7
2026-08-17	$-0.18	$272,226,069	7 / 7
2026-08-18	$-0.18	$272,226,069	7 / 7
2026-08-19	$-0.18	$272,226,069	7 / 7
2026-08-20	$-0.15	$269,037,946	8 / 7
2026-08-21	$-0.15	$269,037,946	8 / 7
2026-08-22	$-0.15	$269,037,946	8 / 7
2026-08-23	$-0.15	$269,037,946	8 / 7
2026-08-24	$-0.15	$269,037,946	8 / 7
2026-08-25	$-0.15	$269,037,946	8 / 7
2026-08-26	$-0.15	$269,037,946	8 / 7
2026-08-27	$-0.15	$269,037,946	8 / 7
2026-08-28	$-0.15	$269,037,946	8 / 7
2026-08-29	$-0.15	$269,037,946	8 / 6
2026-08-30	$-0.15	$269,037,946	8 / 6
2026-08-31	$-0.15	$269,037,946	8 / 6
2026-09-01	$-0.15	$269,037,946	8 / 6
2026-09-02	$-0.15	$269,037,946	8 / 6
2026-09-03	$-0.15	$269,037,946	8 / 6
2026-09-04	$-0.15	$269,037,946	8 / 6
2026-09-05	$-0.15	$269,037,946	8 / 6
2026-09-06	$-0.15	$269,037,946	8 / 6
2026-09-07	$-0.15	$269,037,946	8 / 6
2026-09-08	$-0.15	$269,037,946	8 / 6
2026-09-09	$-0.15	$269,037,946	8 / 6
2026-09-10	$-0.15	$269,037,946	8 / 6
2026-09-11	$-0.15	$269,037,946	8 / 6
2026-09-12	$-0.15	$269,037,946	8 / 6
2026-09-13	$-0.15	$269,037,946	8 / 6
2026-09-14	$-0.15	$269,037,946	8 / 6
2026-09-15	$-0.15	$269,037,946	8 / 6
2026-09-16	$-0.15	$269,037,946	7 / 6
2026-09-17	$-0.15	$269,037,946	7 / 6
2026-09-18	$-0.15	$269,037,946	7 / 6
2026-09-19	$-0.15	$269,037,946	7 / 6
2026-09-20	$-0.15	$269,037,946	7 / 6
2026-09-21	$-0.15	$269,037,946	7 / 6
2026-09-22	$-0.15	$269,037,946	7 / 6
2026-09-23	$-0.15	$269,037,946	7 / 6
2026-09-24	$-0.15	$269,037,946	7 / 6
2026-09-25	$-0.15	$269,037,946	7 / 6
2026-09-26	$-0.15	$277,237,946	7 / 6
2026-09-27	$-0.15	$277,237,946	7 / 6
2026-09-28	$-0.15	$277,237,946	7 / 6
2026-09-29	$-0.15	$277,237,946	7 / 6
2026-09-30	$-0.15	$277,237,946	7 / 6
2026-10-01	$-0.15	$277,237,946	7 / 6
2026-10-02	$-0.15	$277,237,946	7 / 6
2026-10-03	$-0.15	$277,237,946	7 / 6
2026-10-04	$-0.15	$277,237,946	7 / 6
2026-10-05	$-0.15	$277,237,946	7 / 6
2026-10-06	$-0.15	$277,237,946	7 / 6
2026-10-07	$-0.17	$277,237,946	7 / 6
2026-10-08	$-0.02	$303,352,232	7 / 6
2026-10-09	$-0.02	$303,352,232	7 / 6
2026-10-10	$0.03	$317,213,525	7 / 6
2026-10-11	$0.03	$317,213,525	7 / 6
2026-10-12	$0.03	$317,213,525	7 / 6
2026-10-13	$0.03	$317,213,525	7 / 6
2026-10-14	$0.03	$317,213,525	7 / 6
2026-10-15	$0.03	$317,213,525	7 / 6
2026-10-16	$0.03	$317,213,525	7 / 6
2026-10-17	$0.03	$317,213,525	7 / 6
2026-10-18	$0.03	$311,633,713	7 / 6
2026-10-19	$0.03	$311,633,713	7 / 6
2026-10-20	$0.03	$311,633,713	7 / 6
2026-10-21	$0.03	$311,633,713	7 / 6
2026-10-22	$0.03	$311,633,713	7 / 6
2026-10-23	$0.03	$311,633,713	7 / 6
2026-10-24	$0.03	$311,633,713	7 / 6

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	5	1	3
2026-06-01	5	1	3
2026-07-01	5	1	3
2026-08-01	5	1	3
2026-09-01	5	1	3
2026-10-01	5	1	3

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 5 Buy / Strong Buy · 1 Hold · 3 Sell / Strong Sell

0 upgrades0 downgrades1 maintains

Recent actions · Sep 25–Oct 24 · 1 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Target 2026 R&D and SG&A expenses of $325MDirect metric needs a verified mapping
Achieve 2026 revenue of $230M-$270MRevenue: $56.698M

Next proof point

Nov 5, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.8%Typical daily move · historical

Downside history

-34.6%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Novavax, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a high-risk, loss-making biotech business with a partnership and licensing growth angle, rather than a steady compounder. The long-term thesis is intact, with recent results holding in the top half of its industry, but confidence is medium and earnings quality remains fragile.

What's priced into Novavax, Inc.

The valuation evidence points to NVAX being cheap versus peers, while the expectations gap is negative and model confidence is low. The snapshot describes the weak execution picture as only partly reflected, not as a full mix of expensive valuation, weak execution, and turbulent conditions.

What the fundamentals likely do

Near term, revenue may fluctuate: quarterly revenue fell from $140 million in 2026-Q1 to $57 million in 2026-Q2 as the business moved through seasonality and the Sanofi transition, even as management raised its 2026 revenue framework. Cost trends show some discipline, with lower R&D and SG&A expenses in Q2, but progress toward the full-year revenue and expense goals is still mixed.

What Novavax, Inc. hinges on

The key test is whether management maintains its raised 2026 revenue framework without cutting guidance, while staying within its expense goals. Matrix-M licensing progress, including the Pfizer agreement and other exploration agreements, is another growth factor; near-term sector support may depend on healthcare peers continuing to report strong results, while a weakening jobs trend could weigh on the sector.